fda semaglutide shortage declares end to Wegovy and Ozempic FDA ends semaglutide shortage, closing

Hypoglycemia: On their own, GLP-1 RAs have negligible hypoglycemia risk

The Personal Importation Policy allows individuals to import small quantities of unapproved medications for personal use, though this was designed with prescription medications in mind rather than research peptides

The initial adjustment period, while sometimes uncomfortable, gives way to a phase where appetite suppression becomes the primary effect with minimal gastrointestinal symptoms

Diet-related disparities: understanding the problem and accelerating solutions

Wegovy, Zepbound, and Saxenda are being completely removed from the Contract Drugs List for weight loss

A 0.1mL dose would therefore contain 500mcg of the peptide